High-producing biosimilars

 

Category: Biosimilars

Exhibitor: EXCELLGENE SA CELL LINE DEVELOPMENT

Booth No: N/A

 

Characteristic

 

Proprietary CHOExpress® transposon-based technology (JumpExpress®) with clinical and commercial (BLA) track record.
Benefit from our dynamic portfolio of biosimilars, de-risking your preclinical pipeline with seamless integration of upstream (USP) and downstream processes (DSP).

Ready-to-use (off-the-shelf)
Highly productive, robust biosimilar clonal lines
Research (RCB) and cGMP master cell banks (MCB)
Manufacturing processes (USP, DSP) and respective analytics available
Biosimilarity as defined by FDA/EMA guidelines
Cost-effective solutions

Tailored on-demand
Process development (USP, DSP)
Biosimilarity tailor-made to market demands
Scale up to 200L
Analytical packages
Characterization of MCBs
cGMP cell bank ready in less than 11 months

https://www.excellgene.com/biosimilars

 

Other Products

 

• 

  Cell line development, process developement, biosimilars, biobetters, MCB generation, clonality assurance, genome engineering, inducible expression

• 

  Cell line and process development services

• 

  CHOExpress® and HEKExpress® transposon-based platforms

 

 

 

Back